GS-5745: This phase II trial is evaluating nivolumab alone and in combination andecaliximab for the treatment of unresectable or recurrent gastric and gastro-oesophageal cancersA Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Subjects With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Exclusion

• Individuals who have received only neoadjuvant or adjuvant therapy for gastric adenocarcinoma
• Radiotherapy within 28 days of randomization
• Uncontrolled intercurrent illness as outlined in protocol
• History of a concurrent or second malignancy except for those outlined in protocol
• Major surgery, within 28 days of first dose of study drug
• Known positive status for human immunodeficiency virus (HIV)
• Known acute or chronic-active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
• Chronic daily treatment with oral corticosteroids (dose of > 10 mg/day prednisone equivalent) or other immunosuppressive medications within 14 days of randomization
• Known or suspected central nervous system metastases
• Documented myocardial infarction or unstable/uncontrolled cardiac disease within 6 months of randomization
• Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous antibiotics
• Current or history of pneumonitis or interstitial lung disease
• Active known or suspected autoimmune disease with exceptions noted in protocol.
• History of bone marrow, stem cell, or allogenic organ transplantation

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.